



Prevalence of Urogenital Mycoplasmas in Iran and Their Effects on Fertility Potential: A Systematic Review and Meta-Analysis

Mohammad Hossein AHMADI, Akbar MIRSALEHIAN, *Abbas BAHADOR

Dept. of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding Author: Email: abahador@tums.ac.ir

(Received 04 Jun 2015; accepted 14 Dec 2015)

Abstract

Background: Urogenital mycoplasmas are potentially pathogenic species causing genitourinary tract infections that may be initially asymptomatic but can progress and lead to severe complications and threaten reproductive health. However, the overall prevalence rate of this bacterium and its probable impacts on fertility potential have yet to be determined.

Methods: We searched both English and Persian electronic databases using key words such as "*Mycoplasma*," "*Ureaplasma*," "*M. hominis*," "*M. genitalium*," "*U. urealyticum*," "*U. parvum*," "prevalence," and "Iran". Finally, after some exclusion, 29 studies from different regions of Iran were included in our study, and a meta-analysis was performed on collected data.

Results: Urogenital mycoplasmas prevalence for women and men was high and ranged from 2%–40.5% and 2%–44.3%, respectively. The pooled prevalence in the male population was 11.1% (95% CI, 7.4%–16.4%) and in female was 12.8% (95% CI, 9.8%–16.5%). The prevalence of these bacteria was significantly higher in infertile men compared with that in fertile men. A high level of heterogeneity was observed for both men ($I^2 = 92.4\%$; $P < 0.001$) and women ($I^2 = 93.3\%$; $P < 0.001$). Some evidence for publication bias was observed in both men [Egger's test (two-tailed $P = 0.0007$), and Begg's test (two-tailed $P = 0.0151$)] and women [Egger's test (two-tailed $P = 0.0006$), and Begg's test (two-tailed $P = 0.0086$)] analysis.

Conclusion: Since urogenital mycoplasmas may play a role in male infertility, screening strategies, particularly for asymptomatic individuals, and treatment of infected ones, which can reduce consequent complications, looks to be necessary.

Keywords: Urogenital mycoplasmas, Prevalence, Frequency, Fertility potential, Iran

Introduction

Mycoplasmas are in a class of bacteria designated as mollicutes, which lack cell walls, and this characteristic along with their minute size separates them from other bacteria. *Mycoplasma hominis*, *Ureaplasma urealyticum*, *U. parvum*, and *M. genitalium* are potentially pathogenic species frequently isolated from the genitourinary tract and are known as urogenital mycoplasmas (1). These bacteria together with *Neisseria gonorrhoeae* and *Chlamydia trachomatis* are considered among the most prevalent sexually transmitted pathogens that have a global distribution (2-3). Urogenital mycoplasmas are associated with some symptomatic and asymptomatic

genitourinary tract infections in both males and females; for example, they may cause Pelvic Inflammatory Disease (PID) resulting in damage to the fallopian tubes, which may lead to ectopic pregnancy. These bacteria are also associated with non-gonococcal urethritis, endometritis, bacterial vaginosis, preterm delivery, postpartum, or post-abort fever, as well as perinatal disorders such as low birth weight and neonatal bacteremia/meningitis (4-12). The effects of urogenital mycoplasmas on spermatozoa and seminological variables and their role in male or female infertility are controversial and remain unclear (13-18);

however, there is some evidence that *M. genitalium* may cause female infertility, particularly tubal infertility (19-20).

Some of investigators believe that mycoplasmas are genitourinary tract commensals; thus, one of the important problems concerning urogenital mycoplasmas is that there are many clinically asymptomatic carriers silently colonized by these bacteria while these microorganisms are potentially pathogenic and may play a role in urogenital tract infection or affect fertility potential as an opportunistic pathogen, under certain circumstances (21-25). Nevertheless, the majority of asymptomatic infections may remain undetected and consequently untreated.

In Iran, to date, several studies have reported the frequency of urogenital mycoplasmas infections in males and/or females, in which the frequency of these pathogens varies significantly in different surveys. However, most of these studies are local and limited to an individual hospital or a special province or city, and a comprehensive analysis of the overall prevalence of these bacteria, which may be useful to set up control programs for the prevention of sexually transmitted infections (STIs), has not yet been performed.

Thus, the present study was designed to determine the prevalence of urogenital mycoplasmas infections in Iran using a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (26).

Methods

Search strategies

We searched electronic databases, including OVID databases, PubMed, Web of Science, Scopus, and Google Scholar for the prevalence of urogenital mycoplasmas infections in Iran from Nov 1999 to Feb 2015. The search was restricted to original articles published in English that present the prevalence, frequency, or incidence of urogenital mycoplasmas infections in Iranian males or females using the following keywords with the help of Boolean operators (AND, OR): "*Mycoplasma*", "*Ureaplasma*", "urogenital mycoplasmas", "genital

mycoplasmas", "*M. hominis*", "*M. genitalium*", "*U. urealyticum*", "*U. parvum*", "prevalence", "incidence", "frequency", "epidemiology", and "Iran". We additionally searched for other urogenital tract associated mycoplasma species using keywords: "*M. fermentans*", "*M. penetrans*", "*M. primatum*", and "*M. spermatophilum*". In addition to articles published in English, we also looked for relevant articles in Persian published and indexed in Iranian databases, such as Scientific Information Database (SID) (<http://www.sid.ir/>), Magiran (<http://www.magiran.com/>), Irandoc (<http://www.irandoc.ac.ir/>), Regional Information Center for Science and Technology (RICST) (<http://en.ricest.ac.ir/>), and Iranian National Library (<http://www.nlai.ir/>), with similar strategies and related appropriate Persian keywords. References from reviewed articles were also searched for more information.

Inclusion and exclusion criteria

Included studies were all original articles presenting cross-sectional, case-control, or cohort studies on the prevalence of symptomatic or asymptomatic urogenital mycoplasmas infections in Iranian males/females in which the methods for diagnoses were molecular amplification techniques, such as PCR, PCR-restriction fragment length polymorphism (PCR-RFLP), and multiplex PCR. Excluded studies were: 1) those that used detection methods other than nucleic acid amplification techniques (NAAT), including culture or serological methods, such as enzyme-linked immunosorbent assay (ELISA) or immunofluorescence (IF), 2) studies reporting prevalence of mycoplasma species other than urogenital mycoplasmas such as *M. pneumoniae*, 3) studies that included mycoplasma infections in organs or body sites other than the genitourinary tract, and 4) studies reporting the prevalence of urogenital mycoplasmas at the genus level and not the species of mycoplasma. Review articles, congress abstracts, studies reported in languages other than English or Persian, meta-analyses or systematic reviews, duplicate publications of the same study, and articles available only in abstract form were also excluded.

Data extraction and definitions

Variables and information extracted from each study included first author's name, year of publication, study setting, geographical location, participants characteristic, gender, specimen type, number of patients investigated (sample size), bacterial species investigated, type of detection method, and number of positive samples. The articles were reviewed, and relevant data were extracted by two authors independently. Disagreements between reviewers were discussed to obtain consensus.

Statistical analysis

The data were analyzed using Comprehensive Meta-Analysis Software Version 2.0 (Biostat, Englewood, NJ, USA). The prevalence was reported by 95% confidence interval (CI). Cochrane Q-statistic test and I^2 test were performed to estimate heterogeneity between studies, and the random effect model was chosen to estimate the average prevalence because of its conservative summary estimate and because in all calculations (except one in which the fixed effect model was used), I^2 was above 50%. To assess possible publication bias, a funnel plot

along with Begg's rank correlation and Egger's weighted regression methods were used. Two-tailed $P < 0.05$ was considered indicative of a statistically significant publication bias.

Results

A total of 99 articles (59 in English and 40 in Persian) were collected. Through the first screening, 28 articles were excluded on the basis of the title evaluation. After the second assessment, 12 papers were discarded because they had reported mycoplasma infections in organs or body sites other than the genitourinary tract, or investigated other mycoplasma species (such as *M. pneumoniae*). Finally, after full-text evaluation, 30 studies were ruled out on the basis of their detection methods, or because they had reported the prevalence of urogenital mycoplasmas at the genus level and not specified the species, and therefore 29 articles (19 in English and 10 in Persian) published between 2005 and 2015 were selected and included in our analysis (Fig. 1 and Table 1).




Fig. 1: Flow chart of the literature search, systematic review and study selection. *Studies reporting prevalence of mycoplasma species other than urogenital mycoplasmas, such as *M. pneumoniae*; ** surveys reporting the prevalence of urogenital mycoplasmas at genus level

Table 1: Studies included in meta-analysis after final evaluation

Reference	Published year	Province/ City	Sex	Sample	Bacteria spp.	Mean age	Total number of participants	Events number	Events rate (%) (95% CI)	Disease, Complication
(38)	2005	Tehran	F	Endocervical swabs	MH	36	312	50	16.02	Infertility
(39)	2005	Tehran	F	Endocervical swabs	UU	32	312	74	23.7	Infertility
(40)	2006	Tehran	F	Endocervical swabs	MH	32	377	56	14.9	Infertility
(41)	2007	Tehran	M	Semen	MH	35	100	3	3	Infertility
(42)	2007	Tehran	M	Semen	UU	36	200	17	7.5	Fertile & infertile men
(43)	2007	Tehran	F	Endocervical swabs	UU	32	377	85	22.5	Infertility
(44)	2007	Tehran	M	Semen	MH	35	200	40	20	Asymptomatic infertile men
(45)	2008	Tehran	M	Semen	UU	35	246	12	6	Fertile and infertile men
(46)	2008	Tehran	F	Endocervical swabs	MH	31	312	48	15.4	Infertile women
(47)	2009	Tehran	F	Endocervical swabs	MH	31.9	210	42	20	Genital infection
(48)	2009	Tehran	M	Semen	UU	35	200	93	44.3	Fertile & infertile men
(49)	2010	Tehran	M	Semen	MG	38.5	220	11	5.2	Infertility
(50)	2011	Gorgan	F	Vaginal discharge	UU	34	235	10	5	Vaginitis & Vaginitis
(51)	2011	Sabzevar	F	FVU	MH	31	196	18	7.7	Pregnant women
(52)	2012	Tehran	F	Endocervical swabs	UU	39	191	4	2.04	Symptomatic urogenital infection
(53)	2012	Ahvaz	F	Cervicovaginal swab & FVU	MH	34.5	265	52	27.2	Symptomatic urogenital infection
(54)	2013	Kerman	M	Semen	UU	34.5	265	18	6.8	Infertility
(55)	2013	Tehran	M	Semen	UU	34.5	265	28	10.6	Infertility
(56)	2013	Tonekabon	F	vaginal secretions	MH	30	44	13	22.4	Pregnant women
(57)	2013	Tehran	M	FVU	MG	33.5	200	10	22.7	Symptomatic & Asymptomatic men
(58)	2013	Ahvaz	F	cervicovaginal swab & FVU	MG	33.5	200	14	7	Genitourinary infections & healthy females
(59)	2013	Tehran	M	Prostate tissue	MH	34.5	465	18	3.9	Prostatitis
(60)	2014	Sanandaj	F	Endocervical swabs	UU	31	218	41	8.8	Spontaneous abortion & normal pregnancy
(61)	2014	Kerman-shah	F	Cervical swabs	UU	31	218	26	11.9	Cervicitis
(62)	2014	Sanandaj	F	Cervical swabs	MG	32.5	223	11	4.9	Infertility
(63)	2014	Kerman	F	Vaginal swabs	MH	27	104	3	2.9	Infertility
(64)	2014	Kerman	M	Semen	UU	27	104	39	37.5	Infertility
(65)	2014	Tehran	F	Vaginal swab	MG	27	104	3	2.9	Infertility
(66)	2015	Tehran	M	Semen	MH	ND	100	18	18	Infertility
(67)	2015	Tehran	M	Semen	MH	ND	100	15	15	Infertility
(68)	2015	Tehran	F	Vaginal swab	MG	43	100	13	13	Infertility
(69)	2015	Tehran	F	Vaginal swab	MG	32.5	100	10	10	Infertility
(70)	2015	Tehran	F	Vaginal swab	MH	28	165	25	15.2	Pregnant women
(71)	2015	Tehran	F	Vaginal swab	UU	28	165	25	15.2	Pregnant women
(72)	2015	Tehran	M	Semen	MG	ND	45	17	37.8	Fertile & Infertile men

M: males; F: females; FVU: first void urine; MH: *M. hominis*; UU: *U. urealyticum*; MG: *M. genitalium*; UP: *U. parvum*; ND: not determined.

Of the 29 articles included, 16 had studied the prevalence of urogenital mycoplasmas infections in women, 11 in men, and two in both genders;

four articles had studied only *M. hominis*; five only studied *U. urealyticum*, and eight only studied *M. genitalium*; nine articles had studied both *M. homi-*

nis and *U. urealyticum*, two had investigated all three bacteria simultaneously, and there was only one article, explored *U. urealyticum* and *U. parvum* concurrently. We didn't find any articles conducted in Iran about other urogenital tract associated mycoplasma species, including: *M. fermentans*, *M. penetrans*, *M. primatum*, and *M. spermatophilum*. Seven studies (five for men and two for women) were case-control (investigating the frequency of urogenital mycoplasmas in symptomatic-asymptomatic or fertile-infertile individuals, or in females having spontaneous abortion-normal pregnancy), and the rest were cross-sectional. The participants of the cross-sectional studies varied from asymptomatic and fertile individuals to symptomatic men and women having urogenital infections and complications including urethritis, prostatitis, cervicitis, vaginitis, vaginosis, and infertility.

The most commonly collected sample for detection was cervical or endocervical swabs for women, and semen samples for men, but other samples included vaginal discharge or vaginal swabs for women, prostate tissue for men, and first void urine for both genders. Five papers studied other agents in addition to urogenital mycoplasmas, such as *Gardnerella vaginalis*, *Neisseria gonorrhoeae*, and *Chlamydia trachomatis*, simultaneously. Most of the included studies had been performed in Tehran (n=18), which is the capital of Iran, in comparison with ones performed in western (n=3), southeastern (n=3), southwestern (n=2), northern (n=2), and northeastern (n=1) Iran. There were no studies conducted in central, southern or northwestern Iran. The prevalence of urogenital mycoplasma species in different regions of Iran is shown in Table 2.

Table 2: Prevalence of urogenital mycoplasma species in different regions of Iran

Province (City)	Sex	Number of studies	Pooled prevalence of urogenital mycoplasmas ^a (%) (range)				
			All species	MH	UU	MG	UP ^b
Tehran	M	14	10.1 (6.2–16.1)	12.6 (6.7–22.6)	11.5 (4.9–25.0)	10.1 (3.3–26.9)	2.5 (1.0–5.9)
	F	12	19.6 (15.1–25.1)	17.8 (14.5–21.6)	26.4 (18.6–36.0)	5.2 (2.9–9.2)*	NS
Kerman	M	3	16.2 (11.8–22.0)	18.1 (12.0–26.3)	NS	13.0 (7.7–21.1)*	NS
	F	2	13.9 (7.7–23.9)	18.0 (11.6–26.8)*	NS	10.0 (5.5–17.6)*	NS
Ahvaz	M	NS					
	F	4	7.2 (4.8–10.7)	5.1 (2.9–8.8)	9.5 (7.6–11.8)	NS	NS
Sanandaj	M	NS					
	F	4	9.2 (2.7–27.1)	2.9 (0.9–8.6)*	22.2 (6.2–55.1)	2.9 (0.9–8.6)*	NS
Kerman-shah	M	NS					
	F	1	4.9 (2.8–8.7)	NS	NS	4.9 (2.8–8.7)*	NS
Gorgan	M	NS					
	F	2	7.7 (5.6–10.4)	7.7 (4.9–11.8)*	7.7 (4.9–11.8)*	NS	NS
Tonekabon	M	NS					
	F	1	22.7 (12.7–37.3)	NS	NS	22.7 (12.7–37.3)*	NS
Sabzevar	M	NS					
	F	1	2.0 (0.8–5.3)	NS	NS	2.0 (0.8–5.3)*	NS
Total	M	17	11.1 (7.4–16.4)	15.3 (10.6–21.7)	11.5 (4.9–25)	10.7 (4.6–22.9)	2.5 (1.0–5.9)
	F	27	12.8 (9.8–16.5)	12.2 (8.8–16.8)	18.9 (12.7–27.2)	6.2 (3.1–11.8)	NS

M: male; F: female; MH: *M. hominis*; UU: *U. urealyticum*; MG: *M. genitalium*; UP: *U. parvum*; ^aBased on random effects, (95% CI); ^bThere was only one article among included studies, investigated the prevalence of *U. parvum* in males; *There was only one study among included articles in this gender, from this city; NS: no study conducted in this city, about this gender.

The age for women ranged from 14–60 yr (median: 37 yr), and for men from 17–65 yr (median: 41 yr). Three studies had not reported the ages of participants, and nine did not have age-stratified data. Moreover, most of the studies had no usable information on patients' education and/or occupation. However, the highest prevalence of urogenital mycoplasmas between the age groups

belonged to 26–36 yr [38.2% (95% CI, range: 18.8%–57.6%)] and 25–35 yr [42.6% (95%CI, range: 33.7%–51.5%)] for men and women, respectively.

The numbers of participants (sample sizes) in the included studies varied from 45–246 in men and 44–465 in women. Prevalence of urogenital mycoplasmas for men and women ranged from 2%–

40.5% and 2%–44.3%, respectively (95% CI); the lowest rate was related to *M. genitalium* and the highest one was associated to *U. urealyticum*, in both genders. The pooled prevalence of these bacteria in men was 11.1% (95% CI, range: 7.4%–16.4%) and in women was 12.8% (95% CI, range: 9.8%–16.5%); moreover, a high level of heterogeneity was observed in men ($I^2 = 92.4\%$; $P < 0.001$) and women ($I^2 = 93.3\%$; $P < 0.001$). Fig. 2 (A and B) shows the forest plots of the meta-analyses of urogenital mycoplasmas prevalence for men and women, respectively. The funnel plots for meta-analysis of urogenital mycoplasmas prevalence in both men and women suggest some evidence of publication bias [Fig. 4 (A and B)]; two-tailed P for Begg's (based on continuity-corrected normal approximation) and Egger's tests in men was 0.0151 and 0.0007, respectively,

and in women was 0.0086 and 0.0006, correspondingly. We also analyzed the prevalence of each mycoplasma species in men and women, separately; the results are shown in Table 3 and corresponding forest and funnel plots are shown in Fig. 3 (A-F) and 4 (C-H), respectively. Some evidence of publication bias was observed in analysis of *U. urealyticum* prevalence in men (but not in women) [Egger's test (two-tailed $P = 0.0085$), and Begg's test (two-tailed $P = 0.0242$)]. Conversely, no evidence of publication bias was observed in the analysis of other mycoplasma species in men or women [Table 3 and Fig. 4 (C-H)]; however, the number of studies on the prevalence of *M. genitalium* in both men and women and prevalence of *M. hominis* and *U. urealyticum* in men was fewer than 10, and insufficient for an accurate conclusion.




Fig. 2: Forest plots of the meta-analysis of urogenital mycoplasmas prevalence for men (A) and women (B). MH: *M. hominis*; UU: *U. urealyticum*; MG: *M. genitalium*; UP: *U. parvum*




Fig. 3: Forest plots of the meta-analysis of the prevalence of each mycoplasma species. A, C, and E: meta-analysis of prevalence of *M. genitalium*, *M. hominis*, and *U. urealyticum*, respectively in men. B, D, and F: meta-analysis of prevalence of *M. genitalium*, *M. hominis*, and *U. urealyticum*, respectively in women

There were only five case-control studies among the included articles investigated the prevalence of some urogenital mycoplasma species in both fertile and infertile men; the forest plot of meta-analysis showed that the odds ratios for all these studies were above 1, and *P* values for three surveys were below 0.05 (Fig. 5A), indicating that

the prevalence of urogenital mycoplasmas was significantly higher in the case group (infertile men) compared with that in the control group (fertile men); as *I*² was 27.2% (below 50%), the fixed effect model was used; however, the number of studies was fewer than 10, and insufficient for an accurate conclusion; the resulting funnel

plot is shown in Fig. 5B; [no publication bias was observed: Egger's test (two-tailed $P=0.8232$), and Begg's test (two-tailed $P=1.000$)]. Moreover, we found just one article among the included studies

that investigated the prevalence of *U. parvum* and reported its prevalence to be 2% and 3% in fertile and infertile men, respectively (27).




Fig. 4: Funnel plots of the meta-analysis of urogenital mycoplasmas prevalence. A and B: funnel plots for meta-analysis of urogenital mycoplasmas prevalence in men and women, respectively. C, E, and G: funnel plots for meta-analysis of prevalence of *M. genitalium*, *M. hominis*, and *U. urealyticum*, respectively in men. D, F, and H: funnel plots for meta-analysis of prevalence of *M. genitalium*, *M. hominis*, and *U. urealyticum*, respectively in women.




Fig. 5: Meta-analysis of urogenital mycoplasmas prevalence for six case-control studies about men. A: forest plot, B: funnel plot; UU: *U. urealyticum*; MG: *M. genitalium*; UP: *U. parvum*

Table 3: Meta-analysis results for prevalence of each mycoplasma species in included studies

Mycoplasma species*	Number of studies	Sex	Prevalence rate (%) (95% CI)			Heterogeneity test		Begg's test*** P-value (two-tailed)		Egger's test**** P-value (two-tailed)
			Min	Max	Pooled** (range)	I ² (%)	P-value	a	b	
<i>M. genitalium</i>	5	M	2.0	37.8	10.7 (4.6–22.9)	90.6	<0.001	1.0	1.0	0.4
	6	F	2.0	22.7	6.2 (3.1–11.8)	81.6	<0.001	0.9	1.0	0.5
<i>M. hominis</i>	5	M	3.0	22.4	15.3 (10.6–21.7)	70.4	0.009	0.3	0.5	0.2
	11	F	2.9	27.2	12.2 (8.8–16.8)	89.5	<0.001	0.4	0.4	0.04
<i>U. urealyticum</i>	6	M	5.0	40.5	11.5 (4.9–25)	96.1	<0.001	0.06	0.02	0.009
	10	F	7.7	44.3	18.9 (12.7–27.2)	95.0	<0.001	0.3	0.4	0.1
All species	17	M	2.0	40.5	11.1 (7.4–16.4)	92.4	<0.001	0.01	0.02	<0.001
	27	F	2.0	44.3	12.8 (9.8–16.5)	93.3	<0.001	0.009	0.009	<0.001

M: male; F: female; Min: minimum; Max: maximum; a: Kendall's tau without continuity correction; b: Kendall's tau with continuity correction. *There was only one article studied the prevalence of *U. parvum* and reported its prevalence to be 2% and 3% in fertile and infertile men, respectively; **Pooled prevalence (based on random effects); ***Begg and Mazumdar rank correlation; ****Egger's regression intercept.

Discussion

Urogenital mycoplasma species are primarily mucous-associated organisms inhabiting the urogenital tracts of their hosts in close relation with epithelial cells. They may invade host cells and reside

intracellularly; a trait that may assist them to cause chronic infections and give them the ability to evade from host immune responses (5, 27-28). These microorganisms may also cause clinically asymptomatic infections as an opportunistic pathogen, while considering as commensals (21-

25); perhaps due to an imbalance occurred among vaginal microbiota in some circumstances in which some bacteria can multiply and cause diseases (29). However, a considerable amount of urogenital infections caused by these bacteria is asymptomatic and remain undetected and untreated, and consequently the infection may be transmitted to the sexual partner(s). Thus, designing and implementing national control programs to prevent subsequent complications is thought to be necessary. Comprehensive analyses of the overall prevalence of these bacteria, particularly in developing countries (including Iran), may help to carry out such a strategy.

Through this systematic review and meta-analysis, which is the first such study in Iran, we found that prevalence and frequency of urogenital mycoplasma species in men as well as women was highly variable in various studies. There was also a high grade of heterogeneity in participants' characteristics, samples taken for tests, detection methods, sample sizes, and study settings.

As men and women are distinct populations with different indicators of prevalence, corresponding data about each of them were analyzed separately in the present study. Among articles finally included in this analysis, there were no studies conducted in central, southern, or northwestern Iran, and most of them were performed in the capital of Iran (Tehran); this was one of the limitations of our study, which may suggest some participation bias in the generalization of the meta-analysis results. Another restriction of the present study was that many papers conducted in different regions of the country had to be excluded from analysis because their methods of detection were serology (for example, ELISA and IF) or culture, which have lower sensitivity and specificity in comparison with molecular techniques. Furthermore, the samples used for detections were different, and sample sizes in the included studies were different and ranged from 45–246 and 44–465 for men and women, respectively; this may have impacted on the results of analysis, thus we calculated and reported the relative weight for each study. An additional restriction encountered in the current study was that the numbers of in-

cluded studies investigated the prevalence of *M. genitalium* in both men and women, and *M. hominis* and *U. urealyticum* in men were fewer than 10 and insufficient for a good meta-analysis and an accurate conclusion.

In order to find out about possible effects of urogenital mycoplasmas on fertility potential, we analyzed five case-control studies among the included articles investigated the prevalence of urogenital mycoplasmas in both fertile and infertile men; the odds ratios for all of these studies were above 1, *P* values for three surveys (investigated *U. urealyticum*) were below 0.05, the overall odds ratio was 3.2 (95% CI, range: 1.7–6.1), and the overall *P* value was zero; meaning that the prevalence of these bacteria is significantly higher in the case group (infertile men) compared with that in the control group (fertile men), and these bacteria may play a role in male infertility. Nevertheless, because the number of these studies was fewer than 10, we couldn't achieve an exact conclusion about the correlation between urogenital mycoplasmas and male infertility; however, as mentioned in the introduction, this topic is controversial and further case-control or cohort studies are needed to conclude accurately and generalize the results. Moreover, we could not find any interventional or randomized-controlled clinical trial studies assessing the effects of antibiotic therapy for urogenital mycoplasmas infections (particularly asymptomatic infections) on the treatment of probable infertility due to these bacteria.

According to the results of our meta-analysis, the highest pooled prevalence among urogenital mycoplasma species belonged to *M. hominis* in men and *U. urealyticum* in women, and the pooled prevalence of *M. genitalium* was lower than *M. hominis* and *U. urealyticum* in both men and women (Table 3).

As shown in Table 2, the study of urogenital mycoplasmas prevalence in the male population was conducted only in two provinces of Iran, in which the pooled prevalence rate was higher in Kerman [pooled prevalence: 16.2%, (95% CI, range: 11.8%–22%)], rather than Tehran [pooled prevalence: 10.1%, (95% CI, range: 6.2%–

16.1%]); although the number of studies was more in Tehran (n=14) rather than the Kerman province (n=3), and there was no study about *U. urealyticum* from Kerman. In the case of women, the highest prevalence rate belonged to Tonekabon city [22.7%, (95% CI, range: 12.7%–37.3%)], although only one study had been reported from this city on women, and which only investigated the prevalence rate of *M. genitalium*; after that, Tehran province had 12 studies about three mycoplasma species [pooled prevalence: 19.6%, (95% CI, range: 15.1%–25.1%)], and the lowest one belonged to Sabzevar city [prevalence rate: 2%, (95% CI, range: 0.8%–5.3%)], though only one survey had been performed in this city on women about *M. genitalium* prevalence (Table 2).

The World Health Organization has estimated that more than 340 million new cases of STIs occur annually throughout the world, with the highest incidence in developing countries (30).

We could not find similar meta-analysis studies on the prevalence of urogenital mycoplasmas conducted either in neighboring or other countries, to be compared with our analysis in Iran. As mentioned in the results, the highest prevalence of urogenital mycoplasmas in our analysis was in young individuals of 25–36 yr; this finding is consistent with other studies performed in other countries (31-36). However, the overall prevalence of urogenital mycoplasmas varies in different countries and international reports suggest an increase in infections due to these bacteria over the last decade (37). This variability in prevalence rates reported in different countries is perhaps due to a variety in ethnic and social populations, differences in detection methods, types of samples studied, sample sizes, hygiene issues, socio-economic status, age of participants, and absence of regular screening, treatment, and control programs, particularly in some of the developing countries for dealing with the infections caused by these bacteria.

Conclusion

The results show a relatively high prevalence of urogenital mycoplasma species in male as well as

female populations in Iran, particularly in youth (25–36 yr). Urogenital mycoplasmas may play a role in male infertility; this highlights the necessity of planning national programs for adequate diagnosis and screening for genitourinary infections due to these bacteria, particularly asymptomatic infections, and treating infected individuals (including sexual partners) to control STIs and the consequent complications, reduce the carrier rate, and maintain reproductive health and fertility potential. Moreover, further case–control studies or randomized-controlled trials are needed, particularly on the likely influences of these bacteria on reproductive health and their correlation with male/female infertility.

Ethical considerations

Ethical issues (Including plagiarism, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgement

The authors declare that there is no conflict of interests.

References

1. Razin S (2006). The genus *Mycoplasma* and related genera (class Mollicutes). In: *The Prokaryotes: A Handbook on the Biology of Bacteria*. Eds, Dworkin M, Falkow S, Rosenberg E, Schleifer KH, Stackebrandt E. 3rd ed, Springer. New York, pp.: 836-904.
2. Krause W (2008). Male accessory gland infection. *Andrologia*, 40(2):113-6.
3. Gdoura R, Kchaou W, Ammar-Keskes L, Chakroun N, Sellemi A, Znazen A, et al. (2008). Assessment of *Chlamydia trachomatis*, *Ureaplasma urealyticum*, *Ureaplasma parvum*, *Mycoplasma hominis*, and *Mycoplasma genitalium* in semen and first void urine specimens of asymptomatic male partners of infertile couples. *J Androl*, 29(2):198-206.
4. Waites KB, Schelonka RL, Xiao L, Grigsby PL, Novy MJ, editors (2009). Congenital and opportunistic infections: *Ureaplasma* species

- and *Mycoplasma hominis*. *Semin Fetal Neonatal Med*, 14(4):190-9.
5. Waites KB, Katz B, Schelonka RL (2005). Mycoplasmas and ureaplasmas as neonatal pathogens. *Clin Microbiol Rev*, 18(4):757-89.
 6. Taylor-Robinson D, Lamont R (2011). Mycoplasmas in pregnancy. *BJOG*, 118(2):164-74.
 7. Taylor-Robinson D (2007). The role of mycoplasmas in pregnancy outcome. *Best Pract Res Clin Obstet Gynaecol*, 21(3):425-38.
 8. Stellrecht KA, Woron AM, Mishrik NG, Venezia RA (2004). Comparison of multiplex PCR assay with culture for detection of genital mycoplasmas. *J Clin Microbiol*, 42(4):1528-1533.
 9. Stacey C, Munday P, Taylor-Robinson D, Thomas B, Gilchrist C, Ruck F, et al. (1992). A longitudinal study of pelvic inflammatory disease. *Br J Obstet Gynaecol*, 99(12):994-9.
 10. Mårdh P, Weström L (1970). Tubal and cervical cultures in acute salpingitis with special reference to *Mycoplasma hominis* and T-strain mycoplasmas. *Br J Vener Dis*, 46(3):179-86.
 11. Mårdh P (1983). Mycoplasmal PID: a review of natural and experimental infections. *Yale J Biol Med*, 56(5-6):529-36.
 12. Kataoka S, Yamada T, Chou K, Nishida R, Morikawa M, Minami M, et al. (2006). Association between preterm birth and vaginal colonization by mycoplasmas in early pregnancy. *J Clin Microbiol*, 44(1):51-55.
 13. Wang Y, Liang CL, Wu JQ, Xu C, Qin SX, Gao ES (2006). Do *Ureaplasma urealyticum* infections in the genital tract affect semen quality? *Asian J Androl*, 8(5):562-8.
 14. Sanocka-Maciejewska D, Ciupirńska M, Kurpisz M (2005). Bacterial infection and semen quality. *J Reprod Immunol*, 67(1-2):51-6.
 15. Potts JM, Sharma R, Pasqualotto F, Nelson D, Hall G, Agarwal A (2000). Association of *Ureaplasma urealyticum* with abnormal reactive oxygen species levels and absence of leukocytospermia. *J Urol*, 163(6):1775-8.
 16. Ochsendorf FR (2008). Sexually transmitted infections: impact on male fertility. *Andrologia*, 40(2):72-5.
 17. Knox CL, Allan JA, Allan JM, Edirisinghe WR, Stenzel D, Lawrence FA, et al. (2003). *Ureaplasma parvum* and *Ureaplasma urealyticum* are detected in semen after washing before assisted reproductive technology procedures. *Fertil Steril*, 80(4):921-9.
 18. Gdoura R, Keskes-Ammar L, Bouzid F, Eb F, Hammami A, Orfila J (2001). Chlamydia trachomatis and male infertility in Tunisia. *Eur J Contracept Reprod Health Care*, 6(2):102-7.
 19. Svenstrup HF, Fedder J, Kristoffersen SE, Trolle B, Birkelund S, Christiansen G (2008). *Mycoplasma genitalium*, *Chlamydia trachomatis*, and tubal factor infertility—a prospective study. *Fertil Steril*, 90(3):513-20.
 20. Clausen HF, Fedder J, Drasbek M, Nielsen PK, Toft B, Ingerslev HJ, et al. (2001). Serological investigation of *Mycoplasma genitalium* in infertile women. *Hum Reprod*, 16(9):1866-74.
 21. Al-Daghistani HI, Abdel-Dayem M (2010). Clinical significance of asymptomatic urogenital *Mycoplasma hominis* and *Ureaplasma urealyticum* in relation to seminal fluid parameters among infertile Jordanian males. *Middle East Fertil Soc J*, 15(1):29-34.
 22. Günyeli İ, Abike F, Dünder İ, Aslan C, Tapısız ÖL, Temizkan O, et al. (2011). Chlamydia, Mycoplasma and Ureaplasma infections in infertile couples and effects of these infections on fertility. *Arch Gynecol Obstet*, 283(2):379-85.
 23. Klein JO, Buckland D, Finland M (1969). Colonization of newborn infants by mycoplasmas. *N Engl J Med*, 280(19):1025-30.
 24. Pannekoek Y, Trum JW, Bleker OP, van der Veen F, Spanjaard L, Dankert J (2000). Cytokine concentrations in seminal plasma from subfertile men are not indicative of the presence of *Ureaplasma urealyticum* or *Mycoplasma hominis* in the lower genital tract. *J Med Microbiol*, 49(8):697-700.
 25. Salmeri M, Valenti D, Vignera SL, Bellanca S, Morello A, Toscano MA, et al. (2012). Prevalence of *Ureaplasma urealyticum* and *Mycoplasma hominis* infection in unselected infertile men. *J Chemother*, 24(2):81-6.
 26. Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*, 151(4):264-9.
 27. Ammar A, Gad G, Hasan A, Lamia A (2014). Virulence Factors in Mycoplasma of Human Origin. *Egypt J Med Microbiol*, 23(3):29-36.
 28. McAuliffe L, Ellis RJ, Miles K, Ayling RD, Nicholas RA (2006). Biofilm formation by mycoplasma species and its role in

- environmental persistence and survival. *Microbiology*, 152(4):913-22.
29. Taylor-Robinson D, Jensen J, Svenstrup H, Stacey C (2012). Difficulties experienced in defining the microbial cause of pelvic inflammatory disease. *Int J STD AIDS*, 23(1):18-24.
 30. WHO (2010). Global strategy for the prevention and control of sexually transmitted infections: 2006-2015: breaking the chain of transmission, Geneva, Switzerland.
 31. Bayraktar MR, Ozerol IH, Gucluer N, Celik O (2010). Prevalence and antibiotic susceptibility of *Mycoplasma hominis* and *Ureaplasma urealyticum* in pregnant women. *Int J Infect Dis*, 14(2):e90-5.
 32. Pónyai K, Mihalik N, Ostorházi E, Farkas B, Párducz L, Marschalkó M, et al. (2013). Incidence and antibiotic susceptibility of genital mycoplasmas in sexually active individuals in Hungary. *Eur J Clin Microbiol Infect Dis*, 32(11):1423-6.
 33. Song T, Ye A, Xie X, Huang J, Ruan Z, Kong Y, et al. (2014). Epidemiological investigation and antimicrobial susceptibility analysis of ureaplasma species and *Mycoplasma hominis* in outpatients with genital manifestations. *J Clin Pathol*, 67(9):817-20.
 34. Verteramo R, Patella A, Calzolari E, Recine N, Marcone V, Osborn J, et al. (2013). An epidemiological survey of *Mycoplasma hominis* and *Ureaplasma urealyticum* in gynaecological outpatients, Rome, Italy. *Epidemiol Infect*, 141(12):2650-7.
 35. Ye G, Jiang Z, Wang M, Huang J, Jin G, Lu S (2014). The resistance analysis of *Ureaplasma urealyticum* and *Mycoplasma hominis* in female reproductive tract specimens. *Cell Biochem Biophys*, 68(1):207-10.
 36. Zhu C, Liu J, Ling Y, Dong C, Wu T, Yu X, et al. (2012). Prevalence and antimicrobial susceptibility of *Ureaplasma urealyticum* and *Mycoplasma hominis* in Chinese women with genital infectious diseases. *Indian J Dermatol Venereol Leprol*, 78(3):406-7.
 37. Díaz L, Cabrera LE, Fernández T, Ibáñez I, Torres Y, Obregón Y, et al. (2013). Frequency and antimicrobial sensitivity of *Ureaplasma urealyticum* and *Mycoplasma hominis* in patients with vaginal discharge. *MEDICC Rev*, 15(4):45-7.
 38. Najar Peerayeh S, Ale Yasin A (2005). Comparison of PCR with Culture for Detection of *Mycoplasma hominis* in Infertile Women. *TRAUMA MON*, 10(3):183-90. (In Persian).
 39. Najar Peerayeh S, Mirdamad R (2005). Comparison of Culture with Polymerase Chain Reaction for Detection of *Ureaplasma urealyticum* in Endocervical Specimens. *Med J Islam Repub Iran*, 19(2):175-9.
 40. Najar Peerayeh S, Sattari M (2006). Detection of *Ureaplasma urealyticum* and *Mycoplasma hominis* in endocervical specimens from infertile women by polymerase chain reaction. *Middle East Fertil Soc J*, 11(2):104-8.
 41. Soleimani Rahbar A, Golshani M, Fayyaz F, Rafiee Tabatabaei S, Moradi A (2007). Detection of Mycoplasma DNA from the sperm specimens of infertile men by PCR. *Iran J Med Microbiol*, 1(1):47-53. (In Persian).
 42. Zeighami H, Peerayeh SN, Safarlu M (2007). Detection of *Ureaplasma urealyticum* in semen of infertile men by PCR. *Pak J Biol Sci*, 10(21):3960-3.
 43. Najar Peerayeh S, Samimi R (2007). Detection of *Ureaplasma Urealyticum* in Clinical Samples from Infertile Women by Polymerase Chain Reaction. *Iran J Pharmacol Ther*, 6(1):23-6.
 44. Golshani M, Eslami G, Ghobadloo SM, Fallah F, Goudarzi H, Rahbar AS, et al. (2007). Detection of *Chlamydia trachomatis*, *Mycoplasma hominis* and *Ureaplasma urealyticum* by multiplex PCR in semen sample of infertile men. *Iran J Public Health*, 36(2):50-7.
 45. Najar Peerayeh S, Yazdi RS, Zeighami H (2008). Association of *Ureaplasma urealyticum* infection with Varicocele-related infertility. *J Infect Dev Ctries*, 2(2):116-9.
 46. Najar Peerayeh S, Samimi R (2008). Comparison Of Culture With The Polymerase Chain Reaction For Detection Of Gennital Mycoplasma. *Eur J Gen Pract*, 5(2):107-11.
 47. Amirmozafari N, Mirnejad R, Kazemi B, Sariri E, Bojari M, Darkahi FD (2009). Simultaneous Detection of Genital Mycoplasma in Women with Genital Infections by PCR. *J Biol Sci*, 9(8):804-9.
 48. Zeighami H, Peerayeh S, Yazdi R, Sorouri R (2009). Prevalence of *Ureaplasma urealyticum* and *Ureaplasma parvum* in semen of infertile and healthy men. *Int J STD AIDS*, 20(6):387-90.
 49. Ahmadi MH, Amirmozafari N, Kazemi B, Gilani MAS, Jazi FM (2010). Use of PCR to detect

- Mycoplasma hominis* and *Ureaplasma urealyticum* from semen samples of infertile men who referred to Royan Institute in 2009. *Cell J*, 12(3):371-80. (In Persian).
50. Nosrat SB, Ghazisaidei K, Livani S, Dadgar T, Bazueri M, Bagheri H, et al. (2011). The Prevalence of Genital Mycoplasmas in Vaginal Infections in Gorgan, Iran. *Iran J Obstet Gynecol Infertil*, 14(3):20-8. (In Persian).
 51. Haghighi Hasanabad M, Mohammadzadeh M, Bahador A, Fazel N, Rakhshani H, Majnooni A (2011). Prevalence of *Chlamydia trachomatis* and *Mycoplasma genitalium* in pregnant women of Sabzevar-Iran. *Iran J Microbiol*, 3(3):123-8.
 52. Hassani A, Shahrokhi N, Khezardoust S, Sarshar M, Takroosta N, Jamileh N (2012). Detection of *Ureaplasma Urealyticum* and *Mycoplasma hominis* in Clinical Isolates from Women with Genital Tract Infection by PCR. *Iran J Infect Dis Trop Med*, 17(58):45-50. (In Persian).
 53. Moosavian SM, Motamedi H, Malki S, Shahbazian N (2011). Comparison between Prevalence of *Mycoplasma hominis* and *Ureaplasma urealyticum* in Women with Urogenital Infections by Multiplex PCR and Culture Methods. *Med J Tabriz Univ Med Sci*, 33(5):91-7. (In Persian).
 54. Vosoooghi S, Kheirkhah B, Mir-shekar T-R, Karimi Nik A, Hamidavi Mohammadpour S, Mohseni Moghadam N (2013). Molecular detection of *Mycoplasma hominis* from genital secretions of infertile men referred to the Kerman infertility center. *J Microb World*, 6(1):14-22. (In Persian).
 55. Sadrpour P, Bahador A, Asgari S, Bagheri R, Chamani-Tabriz L (2013). Detection of *Chlamydia trachomatis* and *Mycoplasma genitalium* in semen samples of infertile men using multiplex PCR. *Tehran Univ Med J*, 70(10):623-9. (In Persian).
 56. Mohseni R, Sadeghi F, Mirinargesi M, Eghbali M, Dezhkame S, Ghane M (2013). A study on the frequency of vaginal species of *Mycoplasma genitalium*, *Gardnerella vaginalis* and *Neisseria gonorrhoeae* among pregnant women by PCR technique. *Int J Mol Clin Microbiol*, 3(1):231-6.
 57. Yeganeh O, Jeddi-Tehrani M, Yaghmaie F, Kamali K, Heidari-Vala H, Zeraati H, et al. (2013). A survey on the prevalence of *Chlamydia trachomatis* and *Mycoplasma genitalium* infections in symptomatic and asymptomatic men referring to urology clinic of Labbafinejad Hospital, Tehran, Iran. *Iran Red Crescent Med J*, 15(4):340-4.
 58. Maleki S, Motamedi H, Moosavian SM, Shahbazian N (2013). Frequency of *Mycoplasma hominis* and *Ureaplasma urealyticum* in Females With Urogenital Infections and Habitual Abortion History in Ahvaz, Iran; Using Multiplex PCR. *Jundishapur J Microbiol*, 6(6):1-5.
 59. Irajian G, Mirnejad R, Ghorbanpour N (2013). Determining the Prevalence Rate of *Mycoplasma genitalium* in Patients with Prostatitis by PCR-RFLP Technique. *J Ardabil Univ Med Sci*, 13(1):86-92. (In Persian).
 60. Ahmadi A, Khodabandehloo M, Ramazanzadeh R, Farhadifar F, Nikkhoo B, Soofizade N, et al. (2014). Association between *Ureaplasma urealyticum* endocervical infection and spontaneous abortion. *Iran J Microbiol*, 6(6):392-7.
 61. Akya A, Ale Taha SM (2014). The frequency of *Mycoplasma genitalium* infection in women with cervicitis in Kermanshah. *J Clin Res Paramed Sci*, 3(1):56-62. (In Persian).
 62. Mousavi A, Farhadifar F, Mirnejad R, Ramazanzadeh R (2015). Detection of genital mycoplasmal infections among infertile females by multiplex PCR. *Iran J Microbiol*, 6(6):398-403.
 63. Bahaabadi SJ, Moghadam NM, Kheirkhah B, Farsinejad A, Habibzadeh V (2014). Isolation and Molecular Identification of *Mycoplasma hominis* in Infertile Female and Male Reproductive System. *Nephrourol Mon*, 6(6): e22390.
 64. Mohseni Moghadam N, Kheirkhah B, Mirshekari TR, Harandi MF, Tafsiri E (2014). Isolation and molecular identification of *mycoplasma genitalium* from the secretion of genital tract in infertile male and female. *Iran J Reprod Med*, 12(9):601-8.
 65. Sobouti B, Fallah S, Mobayen M, Noorbakhsh S, Ghavami Y (2014). Colonization of *Mycoplasma hominis* and *Ureaplasma urealyticum* in pregnant women and their transmission to offspring. *Iran J Microbiol*, 6(4):219-24.
 66. Safavifar F, Bandehpour M, Hosseiny SJ, Khorramzadeh MR, Shahverdi A, Kazemi B (2015). Mycoplasma Infection in Pyospermic Infertile and Healthy Fertile Men. *Novel biomed*, 3(1):25-9.